GlassScriptPhysician profile
Emma Nauman
NPI 1093287120
$4,084.39
in general payments reported to CMS, 2019-2025
23 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,084 · 2022: $1,491 · 2023: $842 · 2024: $471 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504 · Education: $5.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.32 |
| Education | $5.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $738.19 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $606.10 | 2021-2024 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $337.81 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $324.14 | 2021-2025 | Qelbree, Qelbree |
| Sage Therapeutics, LLC | $257.81 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $244.73 | 2022-2023 | Rexulti |
| Abbvie INC. | $237.27 | 2021-2024 | |
| Bausch Health US, LLC | $230.58 | 2021-2024 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $169.09 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $144.60 | 2021-2022 | |
| Axsome Therapeutics, INC. | $134.20 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $125.75 | 2021-2025 | Rexulti |
| Alkermes, INC. | $109.91 | 2021-2023 | Lybalvi |
| Corium, LLC | $103.17 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $80.11 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $69.57 | 2022 | |
| Idorsia Pharmaceuticals US INC | $38.80 | 2023 | Quviviq |
| Neuronetics, INC. | $32.13 | 2024 | Neurostar Tms Therapy System |
| Janssen Scientific Affairs, LLC | $29.37 | 2022 | |
| Tempus Ai, INC | $20.71 | 2024 | |
| Tris Pharma INC | $18.95 | 2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $17.53 | 2021 | |
| Merck Sharp & Dohme LLC | $13.87 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Nauman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.